Paper32010993
Impact of minimal residual negativity using next generation flow cytometry on outcomes in light chain amyloidosis.
Sidana S and 17 others. Am J Hematol, 2020. Cited by 41 papers, by iCite.
Cite this record
ConductScience Library. Impact of minimal residual negativity using next generation flow cytometry on outcomes in light chain amyloidosis. Papers, record 32010993. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/32010993
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Impact of minimal residual negativity using next generation flow cytometry on outcomes in light chain amyloidosis.
- PubMed
Topics9
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Flow Cytometry | Major topic |
| Immunoglobulin Light-chain Amyloidosis | Major topic |
| Neoplasm, Residual | Major topic |
| Aged | |
| Female | |
| Humans | |
| Male | |
| Middle Aged | |
| Treatment Outcome |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| P50 CA186781 | NCI NIH HHS | United States | P50CA186781 | PubMed and NIH |
Source NIH RePORTER
References23
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 28919633 | Clinical presentation and outcomes in light chain amyloidosis patients with non-evaluable serum free light chains. | Leukemia | 2018 | https://conductscience.org/library/papers/28919633 | PubMed |
| 2 | 29142197 | Proteotoxicity in cardiac amyloidosis: amyloidogenic light chains affect the levels of intracellular proteins in human heart cells. | Sci Rep | 2017 | https://conductscience.org/library/papers/29142197 | PubMed |
| 3 | 25619868 | Consensus guidelines on plasma cell myeloma minimal residual disease analysis and reporting. | Cytometry B Clin Cytom | 2016 | https://conductscience.org/library/papers/25619868 | PubMed |
| 4 | 25115890 | A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis. | Blood | 2014 | https://conductscience.org/library/papers/25115890 | PubMed |
| 5 | 23624626 | Human amyloidogenic light chain proteins result in cardiac dysfunction, cell death, and early mortality in zebrafish. | Am J Physiol Heart Circ Physiol | 2013 | https://conductscience.org/library/papers/23624626 | PubMed |
| 6 | 27511158 | International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. | Lancet Oncol | 2016 | https://conductscience.org/library/papers/27511158 | PubMed |
| 7 | 29568089 | The importance of bone marrow examination in patients with light chain amyloidosis achieving a complete response. | Leukemia | 2018 | https://conductscience.org/library/papers/29568089 | PubMed |
| 8 | 16794250 | Dangerous small B-cell clones. | Blood | 2006 | https://conductscience.org/library/papers/16794250 | PubMed |
| 9 | 30249784 | Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma. | Blood | 2018 | https://conductscience.org/library/papers/30249784 | PubMed |
| 10 | 29795385 | Evaluation of minimal residual disease using next-generation flow cytometry in patients with AL amyloidosis. | Blood Cancer J | 2018 | https://conductscience.org/library/papers/29795385 | PubMed |
| 11 | 23733781 | Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study. | J Clin Oncol | 2013 | https://conductscience.org/library/papers/23733781 | PubMed |
| 12 | 27118453 | Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients. | Blood | 2016 | https://conductscience.org/library/papers/27118453 | PubMed |
| 13 | 23091105 | New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. | J Clin Oncol | 2012 | https://conductscience.org/library/papers/23091105 | PubMed |
| 14 | 27729322 | The prognostic value of multiparametric flow cytometry in AL amyloidosis at diagnosis and at the end of first-line treatment. | Blood | 2017 | https://conductscience.org/library/papers/27729322 | PubMed |
| 15 | 31544536 | Survival impact of achieving minimal residual negativity by multi-parametric flow cytometry in AL amyloidosis. | Amyloid | 2020 | https://conductscience.org/library/papers/31544536 | PubMed |
| 16 | 28287637 | Minimal residual disease (MRD) assessment by flow cytometry after ASCT for AL amyloidosis: are we there yet? | Bone Marrow Transplant | 2017 | https://conductscience.org/library/papers/28287637 | PubMed |
| 17 | 27632282 | Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma: A Meta-analysis. | JAMA Oncol | 2017 | https://conductscience.org/library/papers/27632282 | PubMed |
| 18 | 28550043 | AL amyloidosis patients with low amyloidogenic free light chain levels at first diagnosis have an excellent prognosis. | Blood | 2017 | https://conductscience.org/library/papers/28550043 | PubMed |
| 19 | 28104919 | Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma. | Leukemia | 2017 | https://conductscience.org/library/papers/28104919 | PubMed |
| 20 | 29964192 | Prognostic Significance of Stringent Complete Response after Stem Cell Transplantation in Immunoglobulin Light Chain Amyloidosis. | Biol Blood Marrow Transplant | 2018 | https://conductscience.org/library/papers/29964192 | PubMed |
Cited by20
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 41 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41462937 | Proving Bone Marrow Plasma Cell Clonality by Flow Cytometry: An Important Tool in the Diagnosis of Immunoglobulin Light-Chain Amyloidosis. | Biomedicines | 2025 | https://conductscience.org/library/papers/41462937 | PubMed |
| 39587494 | Light-chain amyloidosis with concomitant symptomatic myeloma (CRAB-SLiM features): clinical characteristics, cytogenetic abnormalities, and outcomes. | BMC Cancer | 2024 | https://conductscience.org/library/papers/39587494 | PubMed |
| 39485557 | Early minimal residual disease eradication in light chain amyloidosis generates deeper and faster cardiac response. | Clin Exp Med | 2024 | https://conductscience.org/library/papers/39485557 | PubMed |
| 39384609 | Phase II study of novel CXCR2 agonist and Plerixafor for rapid stem cell mobilization in patients with multiple myeloma. | Blood Cancer J | 2024 | https://conductscience.org/library/papers/39384609 | PubMed |
| 39179452 | Autologous stem cell transplantation in AL amyloidosis: Muddy waters. | Blood Rev | 2024 | https://conductscience.org/library/papers/39179452 | PubMed |
| 39157610 | HOVON 104, long-term follow-up of bortezomib-dexamethasone induction therapy followed by autologous stem cell transplantation in newly diagnosed AL amyloidosis patients. | EJHaem | 2024 | https://conductscience.org/library/papers/39157610 | PubMed |
| 39139790 | A bibliometric analysis of light chain amyloidosis from 2005 to 2024: research trends and hot spots. | Front Med (Lausanne) | 2024 | https://conductscience.org/library/papers/39139790 | PubMed |
| 38619663 | Minimal residual disease in systemic light chain amyloidosis: a systematic review and meta-analysis. | J Cancer Res Clin Oncol | 2024 | https://conductscience.org/library/papers/38619663 | PubMed |
| 36620914 | Bad players in AL amyloidosis in the current era of treatment. | Expert Rev Hematol | 2023 | https://conductscience.org/library/papers/36620914 | PubMed |
| 36215675 | Graded Cardiac Response Criteria for Patients With Systemic Light Chain Amyloidosis. | J Clin Oncol | 2023 | https://conductscience.org/library/papers/36215675 | PubMed |
| 34681575 | Biomarkers in AL Amyloidosis. | Int J Mol Sci | 2021 | https://conductscience.org/library/papers/34681575 | PubMed |
| 34006856 | Comprehensive Review of AL amyloidosis: some practical recommendations. | Blood Cancer J | 2021 | https://conductscience.org/library/papers/34006856 | PubMed |
| 33966111 | Clinical value of minimal residual disease assessed by multiparameter flow cytometry in amyloid light chain amyloidosis. | J Cancer Res Clin Oncol | 2022 | https://conductscience.org/library/papers/33966111 | PubMed |
| 33594045 | Minimal residual disease negativity by next-generation flow cytometry is associated with improved organ response in AL amyloidosis. | Blood Cancer J | 2021 | https://conductscience.org/library/papers/33594045 | PubMed |
| 33230879 | Characterization and prognostic implication of delayed complete response in AL amyloidosis. | Eur J Haematol | 2021 | https://conductscience.org/library/papers/33230879 | PubMed |
| 33099434 | Future Perspectives. | Hematol Oncol Clin North Am | 2020 | https://conductscience.org/library/papers/33099434 | PubMed |
| 32885146 | Systemic AL Amyloidosis: Current Approaches to Diagnosis and Management. | Hemasphere | 2020 | https://conductscience.org/library/papers/32885146 | PubMed |
| 32754033 | Treating Protein Misfolding Diseases: Therapeutic Successes Against Systemic Amyloidoses. | Front Pharmacol | 2020 | https://conductscience.org/library/papers/32754033 | PubMed |
| 32634163 | Diverse patterns of antibody variable gene repertoire disruption in patients with amyloid light chain (AL) amyloidosis. | PLoS One | 2020 | https://conductscience.org/library/papers/32634163 | PubMed |
| 32531894 | CD38 and Anti-CD38 Monoclonal Antibodies in AL Amyloidosis: Targeting Plasma Cells and beyond. | Int J Mol Sci | 2020 | https://conductscience.org/library/papers/32531894 | PubMed |
Genes8
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CD19 | 930 | PubTator's text mining | https://conductscience.org/library/genes/930 | NCBI Gene |
| CD27 | 939 | PubTator's text mining | https://conductscience.org/library/genes/939 | NCBI Gene |
| CD38 | 952 | PubTator's text mining | https://conductscience.org/library/genes/952 | NCBI Gene |
| CD81 | 975 | PubTator's text mining | https://conductscience.org/library/genes/975 | NCBI Gene |
| KIT | 3815 | PubTator's text mining | https://conductscience.org/library/genes/3815 | NCBI Gene |
| NCAM1 | 4684 | PubTator's text mining | https://conductscience.org/library/genes/4684 | NCBI Gene |
| PTPRC | 5788 | PubTator's text mining | https://conductscience.org/library/genes/5788 | NCBI Gene |
| SDC1 | 6382 | PubTator's text mining | https://conductscience.org/library/genes/6382 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/32010993
GET https://conductscience.org/api/papers/v1/32010993/references?page=2